Loading…
Dividends declared (per SOCE filings): FY2018 0 · FY2019 241 · FY2020 223 — 3-yr total 463
Operates in Healthcare Services — In-patient & out-patient services. Per the activity note to the FY2022 annual report, the company provides medical services and pharmaceutical services. Founded on 24 July 2001; provides medical and pharmaceutical services; capital repairs conducted in 2022.
Subsidiary of Israeli-Georgian Medical Research Clinic Helsicore (100.0%)
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 75.9% | 68.4% | 72.2% | 26.8% | 94.9% |
| EBITDA Margin | 128.9% | 15.3% | 6.6% | 18.4% | -11.3% |
| EBITDAR | 3,221 | 402 | 158 | 557 | -127 |
| EBITDAR Margin | 128.9% | 15.4% | 6.7% | 18.4% | -11.3% |
| EBIT Margin | 128.9% | 14.7% | 4.7% | 18.4% | -11.3% |
| Net Profit Margin | 177.1% | 13.6% | 5.3% | 17.2% | -9.8% |
| Operating Expense % of Sales | 53.0% | 53.5% | 65.6% | 8.4% | 106.1% |
| Returns | |||||
| Return on Assets (ROA) | 343.7% | 18.9% | 4.9% | 19.4% | -3.6% |
| Return on Equity (ROE) | 1302.3% | 27.1% | 6.1% | 21.4% | -3.7% |
| ROIC [EBIT / Invested Capital] | 661.7% | 26.2% | 5.1% | 24.4% | -4.4% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 17.7% | 10.7% | 5.4% | 0.0% | 0.0% |
| Debt-to-Equity | 0.67x | 0.15x | 0.07x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.07x | 0.50x | 0.86x | 0.00x | N/A |
| Equity-to-Assets | 26.4% | 69.7% | 81.5% | 90.6% | 97.1% |
| Net Debt | 147 | 151 | 126 | -143 | -113 |
| Cash & Equivalents | 81 | 50 | 10 | 143 | 113 |
| Total Debt | 227 | 201 | 135 | N/A | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 1.03x | 2.35x | 1.95x | 0.91x | 5.63x |
| Quick Ratio | 0.94x | 2.13x | 1.58x | 0.91x | 5.63x |
| Cash Ratio | 0.14x | 0.14x | 0.03x | 0.05x | 1.26x |
| Total Current Assets | 610 | 867 | 645 | 2,427 | 501 |
| Total Current Liabilities | 593 | 369 | 331 | 2,678 | 89 |
| Inventory | 56 | 79 | 122 | N/A | N/A |
| Trade Receivables | 496 | 704 | 487 | 448 | 156 |
| Trade Payables | 593 | 369 | 331 | 245 | 89 |
| Net Working Capital | 18 | 498 | 314 | -251 | 412 |
| Net Working Capital % of Revenue | 0.7% | 19.0% | 13.3% | -8.3% | 36.6% |
| Trade Working Capital | -40 | 414 | 278 | 203 | 67 |
| Trade Working Capital % of Revenue | -1.6% | 15.8% | 11.8% | 6.7% | 5.9% |
| Change in Trade Working Capital | N/A | 454 | -135 | -75 | -137 |
| Turnover & efficiency | |||||
| Inventory Turnover | 10.75x | 10.42x | 5.39x | N/A | N/A |
| Days Inventory Outstanding (DIO) | 33.9 | 35.0 | 67.7 | N/A | N/A |
| Receivables Turnover | 5.03x | 3.71x | 4.85x | 6.75x | 7.24x |
| Days Sales Outstanding (DSO) | 72.5 | 98.3 | 75.3 | 54.1 | 50.4 |
| Payables Turnover | 1.02x | 2.24x | 1.98x | 9.04x | 0.65x |
| Days Payable Outstanding (DPO) | 358.7 | 163.3 | 184.0 | 40.4 | 561.3 |
| Cash Conversion Cycle | -252.3 days | -30.0 days | -41.0 days | 13.7 days | -510.9 days |
| Asset Turnover | 1.94x | 1.39x | 0.94x | 1.13x | 0.37x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 8 | -30 | -42 | 146 | -96 |
| Free Cash Flow (OCF − Capex proxy) | 8 | -30 | -42 | 146 | -96 |
| Cash Conversion (OCF / EBITDA) | 0.3% | -7.6% | -26.8% | 26.2% | N/A |
| Dividends Declared | 0 | 241 | 223 | N/A | N/A |
| Dividend Payout Ratio | 0.0% | 67.8% | 179.6% | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →